ACVR2A and neoplasm: Mice treated with Bu-Cy showed significant increases in activin A receptors, ACVR2A, and ACVR1B, indicating that the state of the tumor microenvironment (such as activin A increase under chemotherapy) could augment activin A responsiveness.